130 related articles for article (PubMed ID: 21338443)
1. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity.
Depondt C; Godard P; Espel RS; Da Cruz AL; Lienard P; Pandolfo M
Eur J Neurol; 2011 Sep; 18(9):1159-64. PubMed ID: 21338443
[TBL] [Abstract][Full Text] [Related]
2. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.
Chung WH; Chang WC; Lee YS; Wu YY; Yang CH; Ho HC; Chen MJ; Lin JY; Hui RC; Ho JC; Wu WM; Chen TJ; Wu T; Wu YR; Hsih MS; Tu PH; Chang CN; Hsu CN; Wu TL; Choon SE; Hsu CK; Chen DY; Liu CS; Lin CY; Kaniwa N; Saito Y; Takahashi Y; Nakamura R; Azukizawa H; Shi Y; Wang TH; Chuang SS; Tsai SF; Chang CJ; Chang YS; Hung SI; ;
JAMA; 2014 Aug; 312(5):525-34. PubMed ID: 25096692
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine.
López M; Dorado P; Monroy N; Alonso ME; Jung-Cook H; Machín E; Peñas-Lledó E; Llerena A
Drug Metabol Drug Interact; 2011; 26(1):5-12. PubMed ID: 21557672
[TBL] [Abstract][Full Text] [Related]
4. Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients.
Thakkar AN; Bendkhale SR; Taur SR; Gogtay NJ; Thatte UM
Neurol India; 2012; 60(6):577-80. PubMed ID: 23287317
[TBL] [Abstract][Full Text] [Related]
5. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation.
Twardowschy CA; Werneck LC; Scola RH; De Paola L; Silvado CE
Arq Neuropsiquiatr; 2011 Apr; 69(2A):153-8. PubMed ID: 21537551
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance.
Kousar S; Wafai ZA; Wani MA; Jan TR; Andrabi KI
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):504-16. PubMed ID: 25943175
[TBL] [Abstract][Full Text] [Related]
7. [Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy].
Yamamoto Y; Takahashi Y; Nishimura S; Ikumi Y; Mishima N; Kagawa Y
Yakugaku Zasshi; 2011; 131(5):809-15. PubMed ID: 21532277
[TBL] [Abstract][Full Text] [Related]
8. The clinical impact of pharmacogenetics on the treatment of epilepsy.
Löscher W; Klotz U; Zimprich F; Schmidt D
Epilepsia; 2009 Jan; 50(1):1-23. PubMed ID: 18627414
[TBL] [Abstract][Full Text] [Related]
9. Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children.
Suvichapanich S; Jittikoon J; Wichukchinda N; Kamchaisatian W; Visudtibhan A; Benjapopitak S; Nakornchai S; Manuyakorn W; Mahasirimongkol S
J Hum Genet; 2015 Aug; 60(8):413-7. PubMed ID: 25994870
[TBL] [Abstract][Full Text] [Related]
10. The role of CYP2C9 polymorphisms in phenytoin-related cerebellar atrophy.
Twardowschy CA; Werneck LC; Scola RH; Borgio JG; De Paola L; Silvado C
Seizure; 2013 Apr; 22(3):194-7. PubMed ID: 23298603
[TBL] [Abstract][Full Text] [Related]
11. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms.
Dorado P; López-Torres E; Peñas-Lledó EM; Martínez-Antón J; Llerena A
Pharmacogenomics J; 2013 Aug; 13(4):359-61. PubMed ID: 22641027
[TBL] [Abstract][Full Text] [Related]
12. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.
Tate SK; Depondt C; Sisodiya SM; Cavalleri GL; Schorge S; Soranzo N; Thom M; Sen A; Shorvon SD; Sander JW; Wood NW; Goldstein DB
Proc Natl Acad Sci U S A; 2005 Apr; 102(15):5507-12. PubMed ID: 15805193
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.
Kesavan R; Narayan SK; Adithan C
Eur J Clin Pharmacol; 2010 Jul; 66(7):689-96. PubMed ID: 20390258
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP2C9 genetic polymorphism and undernourishment on plasma-free phenytoin concentrations in epileptic patients.
Ramasamy K; Narayan SK; Shewade DG; Chandrasekaran A
Ther Drug Monit; 2010 Dec; 32(6):762-6. PubMed ID: 21068649
[TBL] [Abstract][Full Text] [Related]
15. The association between CYP2C9/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: A systematic review and meta-analysis
.
Liao K; Liu Y; Ai CZ; Yu X; Li W
Int J Clin Pharmacol Ther; 2018 Jul; 56(7):337-346. PubMed ID: 29628024
[TBL] [Abstract][Full Text] [Related]
16. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy.
Sánchez MB; Herranz JL; Leno C; Arteaga R; Oterino A; Valdizán EM; Nicolás JM; Adín J; Armijo JA
Seizure; 2010 Mar; 19(2):93-101. PubMed ID: 20064729
[TBL] [Abstract][Full Text] [Related]
17. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
Franco V; Perucca E
Expert Opin Drug Metab Toxicol; 2015; 11(8):1269-79. PubMed ID: 26037375
[TBL] [Abstract][Full Text] [Related]
18. An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
Chang WC; Hung SI; Carleton BC; Chung WH
Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):723-734. PubMed ID: 32510242
[TBL] [Abstract][Full Text] [Related]
19. Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients.
Zeng K; Wang X; Xi Z; Yan Y
Clin Neurol Neurosurg; 2010 May; 112(4):291-5. PubMed ID: 20071075
[TBL] [Abstract][Full Text] [Related]
20. Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients.
Hung CC; Huang HC; Gao YH; Chang WL; Ho JL; Chiou MH; Hsieh YW; Liou HH
Pharmacogenomics; 2012 Sep; 13(12):1339-49. PubMed ID: 22966884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
